Surface modification of lipid nanoparticles for gene therapy
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Belal Tafech und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Lipids, Nanoparticles. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Mitacs Canada, Providence Healthcare, Canadian Institute of Health Research.
Abstract (Originalsprache)
Gene therapies have the potential to target and effectively treat a variety of diseases including cancer as well as genetic, neurological, and autoimmune disorders. Although we have made significant advances in identifying non‐viral strategies to deliver genetic cargo, certain limitations remain. In general, gene delivery is challenging for several reasons including the instabilities of nucleic acids to enzymatic and chemical degradation and the presence of restrictive biological barriers such as cell, endosomal and nuclear membranes. The emergence of lipid nanoparticles (LNPs) helped overcome many of these challenges. Despite its success, further optimization is required for LNPs to yield efficient gene delivery to extrahepatic tissues, as LNPs favor accumulation in the liver after systemic administration. In this mini‐review, we provide an overview of current preclinical approaches in that LNP surface modification was leveraged for cell and tissue targeting by conjugating aptamers, antibodies, and peptides among others. In addition to their cell uptake and efficiency‐enhancing effects, we outline the (dis‐)advantages of the different targeting moieties and commonly used conjugation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
- Center of Biological Design, Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin, Germany.
- Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
ORCID-Profile: Sarah Hedtrich
Förderung
- Mitacs Canada
- Providence Healthcare
- Canadian Institute of Health Research
- LEO Foundation
- Foundation Charité
- Mitacs
- Canadian Institutes of Health Research - Antimicrobial Resistance Research Initiative
- LEO Fondet
Zitieren
APA
Tafech, B., Mohabatpour, F., & Hedtrich, S. (2024). Surface modification of lipid nanoparticles for gene therapy. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3642
Vancouver
Tafech B, Mohabatpour F, Hedtrich S. Surface modification of lipid nanoparticles for gene therapy. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3642
BibTeX
@article{Tafech2024,
author = {Tafech, Belal and Mohabatpour, Fatemeh and Hedtrich, Sarah},
title = {Surface modification of lipid nanoparticles for gene therapy},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3642}
}
EUVIMED